{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:18:08Z","timestamp":1784729888298,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>On January 31, 2023, the province of British Columbia (BC) introduced a 3-year drug decriminalization initiative, with a goal of increasing access, engagement, and retention in drug use treatment. There is limited information on the operational characteristics of opioid agonist treatment (OAT) sites in BC. These\u00a0data are required to monitor the impacts of decriminalization on these outcomes. This study sought to characterize OAT service operations and examine any preliminary operational changes following decriminalization, from the perspectives of OAT site staff.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between March and April 2024, a cross-sectional, online self-report survey was distributed to OAT sites across BC, completed by site representatives. Questions focused on OAT service operations, including service capacity, treatment retention, and clientele demographics, as well as potential changes to service operations due to decriminalization. Data were analyzed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28 OAT sites from across BC completed the survey. Findings suggest that decriminalization has had limited impacts on OAT site operations within the first year of the policy\u2019s implementation. However, several sites reported early signals of change related to client socio-demographics, including seeing more male and younger clients, as well as an increase in demand on their staff and resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite minimal changes to OAT site operations within the first year of BC\u2019s decriminalization policy, findings suggest the need for increased staff training on decriminalization and continued investments into OAT to better support the anticipated demand on services if decriminalization is to successfully reach its goal of improving access to treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.17269\/s41997-025-01060-2","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:59:30Z","timestamp":1749466770000},"page":"518-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Examining opioid agonist treatment (OAT) site operations and early signals of change in the first year of British Columbia\u2019s drug decriminalization policy: Insights from a provincial survey"],"prefix":"10.17269","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-9554","authenticated-orcid":false,"given":"Cayley","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"MacKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Crichlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Patenaude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Imtiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farihah","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"1","key":"1060_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12954-022-00725-2","volume":"19","author":"G Bardwell","year":"2022","unstructured":"Bardwell, G., Mansoor, M., Van Zwietering, A., Cleveland, E., Snell, D., & Kerr, T. (2022). The \u201cgoldfish bowl\u201d: A qualitative study of the effects of heightened surveillance on people who use drugs in a rural and coastal Canadian setting. Harm Reduction Journal, 19(1), 136. https:\/\/doi.org\/10.1186\/s12954-022-00725-2","journal-title":"Harm Reduction Journal"},{"key":"1060_CR2","unstructured":"BC Centre for Disease Control (BCCDC). (2023). Unregulated drug poisoning emergency dashboard. In (October 16, 2023 ed.). BCCDC."},{"issue":"6","key":"1060_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","volume":"38","author":"L Belzak","year":"2018","unstructured":"Belzak, L., & Halverson, J. (2018). Evidence synthesis - the opioid crisis in Canada: A national perspective. Health Promotion and Chronic Disease Prevention in Canada, 38(6), 224\u2013233.","journal-title":"Health Promotion and Chronic Disease Prevention in Canada"},{"key":"1060_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102938","volume":"91","author":"S Boyd","year":"2021","unstructured":"Boyd, S. (2021). Heroin and the illegal drug overdose death epidemic: A history of missed opportunities and resistance. The International Journal of Drug Policy, 91, Article 102938. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102938","journal-title":"The International Journal of Drug Policy"},{"key":"1060_CR5","unstructured":"British Columbia Centre on Substance Use (BCCSU). (2023). A guideline for the clinical management of opioid use disorder - 2023 update. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/12\/BC-OUD-Treatment-Guideline_2023-Update.pdf. Accessed 12 Jul 2024."},{"key":"1060_CR6","unstructured":"British Columbia Centre on Substance Use (BCCSU), B.C. Ministry of Health, & B.C. Ministry of Mental Health and Addictions. (2022). Risk mitigation in the context of dual health emergencies\u2014interim clinical guidance: update. British Columbia Centre on Substance Use (BCCSU). https:\/\/www.bccsu.ca\/COVID-19"},{"issue":"34","key":"1060_CR7","doi-asserted-by":"publisher","first-page":"E967","DOI":"10.1503\/cmaj.200191","volume":"192","author":"A Crabtree","year":"2020","unstructured":"Crabtree, A., Lostchuk, E., Chong, M., Shapiro, A., & Slaunwhite, A. (2020). Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada. Canadian Medical Association Journal, 192(34), E967\u2013E972.","journal-title":"Canadian Medical Association Journal"},{"key":"1060_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103879","volume":"110","author":"Z Cui","year":"2022","unstructured":"Cui, Z., Bach, P., Ti, L., Hayashi, K., Morgan, J., Milloy, M. J., & Kerr, T. (2022). Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada. International Journal of Drug Policy, 110, Article 103879. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103879","journal-title":"International Journal of Drug Policy"},{"key":"1060_CR9","doi-asserted-by":"publisher","unstructured":"Daowd, K., Ferguson, M., Liu, L., Loyal, J., Lock, K., Graham, B.,\u00a0\u2026\u00a0Buxton, J. A. (2023). Awareness, predictors and outcomes of drug alerts among people who access harm reduction services in British Columbia, Canada: Findings from a 2021 cross-sectional survey. BMJ Open, 13(5), e071379. https:\/\/doi.org\/10.1136\/bmjopen-2022-071379","DOI":"10.1136\/bmjopen-2022-071379"},{"issue":"1","key":"1060_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12954-024-00952-9","volume":"21","author":"L de Saxe Zerden","year":"2024","unstructured":"de Saxe Zerden, L., Ware, O. D., Lombardi, B. N., & Lombardi, B. M. (2024). Harm reduction workforce, behavioral health, and service delivery in the USA: A cross-sectional study. Harm Reduction Journal, 21(1), 36. https:\/\/doi.org\/10.1186\/s12954-024-00952-9","journal-title":"Harm Reduction Journal"},{"key":"1060_CR11","doi-asserted-by":"publisher","unstructured":"Dong, H., Hayashi, K., Milloy, M. J., DeBeck, K., Singer, J., Wong, H.,\u00a0\u2026\u00a0Kerr, T. (2020). Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend, 212, 108005. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108005","DOI":"10.1016\/j.drugalcdep.2020.108005"},{"issue":"7","key":"1060_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl, J. K., Morin, K., Leinonen, E., & Marsh, D. C. (2017). The state of opioid agonist therapy in Canada 20 years after federal oversight. Canadian Journal of Psychiatry, 62(7), 444\u2013450. https:\/\/doi.org\/10.1177\/0706743717711167","journal-title":"Canadian Journal of Psychiatry"},{"issue":"3","key":"1060_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/ADM.0000000000000476","volume":"13","author":"JK Eibl","year":"2019","unstructured":"Eibl, J. K., Wilton, A. S., Franklyn, A. M., Kurdyak, P., & Marsh, D. C. (2019). Evaluating the impact of prescribed versus nonprescribed benzodiazepine use in methadone maintenance therapy: Results from a population-based retrospective cohort study. Journal of Addiction Medicine, 13(3), 182\u2013187.","journal-title":"Journal of Addiction Medicine"},{"key":"1060_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-016-0127-9","volume":"14","author":"AM Franklyn","year":"2017","unstructured":"Franklyn, A. M., Eibl, J. K., Gauthier, G., Pellegrini, D., Lightfoot, N. E., & Marsh, D. C. (2017). The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. Harm Reduction Journal, 14, 1\u20139.","journal-title":"Harm Reduction Journal"},{"key":"1060_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmph.2020.100609","volume":"11","author":"V Giang","year":"2020","unstructured":"Giang, V., Thulien, M., McNeil, R., Sedgemore, K., Anderson, H., & Fast, D. (2020). Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis. SSM - Population Health, 11, Article 100609. https:\/\/doi.org\/10.1016\/j.ssmph.2020.100609","journal-title":"SSM - Population Health"},{"key":"1060_CR16","unstructured":"Gilroy, E. K. (2023). Drug decriminalization and harm reduction in Portugal: Can policy innovation overcome stigma?\u00a0University of Washington."},{"key":"1060_CR17","unstructured":"Government of Canada. (2024). Opioid- and stimulant-related harms in Canada. Government of Canada. Retrieved from https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids\/maps?index=1. Accessed 10 Sept 2021."},{"key":"1060_CR18","doi-asserted-by":"crossref","unstructured":"Greene, C., Urbanik, M., & Geldart, R. (2022). Experiences with compounding surveillance and social control as a barrier to safe consumption service access. SSM - Qualitative Research in Health, 2, 100055.","DOI":"10.1016\/j.ssmqr.2022.100055"},{"key":"1060_CR19","doi-asserted-by":"publisher","unstructured":"Hodgson, K., Bowles, J. M., Mansoor, M., Rooke, E., & Bardwell, G. (2024). \u2018I\u2019m on the coast and I\u2019m on methadone\u2019: A qualitative study examining access to opioid agonist treatment in rural and coastal British Columbia. Canadian Journal of Rural Medicine. Journal Canadien de la M\u00e9decine Rurale, 29(3), 117\u2013124. https:\/\/doi.org\/10.4103\/cjrm.cjrm_56_23","DOI":"10.4103\/cjrm.cjrm_56_23"},{"key":"1060_CR20","unstructured":"Ministry of Mental Health and Addictions. (2023). B.C. takes action to save lives, build new connections of care with drug decriminalization. https:\/\/news.gov.bc.ca\/releases\/2023MMHA0005-000106#:~:text=%E2%80%9CThe%20decriminalization%20of%20people%20who,connect%20people%20to%20the%20health. Accessed 12 Jul 2024."},{"issue":"3","key":"1060_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamainternmed.2023.7570","volume":"184","author":"HV Nguyen","year":"2024","unstructured":"Nguyen, H. V., Mital, S., Bugden, S., & McGinty, E. E. (2024). British Columbia\u2019s safer opioid supply policy and opioid outcomes. JAMA Internal Medicine, 184(3), 256\u2013264. https:\/\/doi.org\/10.1001\/jamainternmed.2023.7570","journal-title":"JAMA Internal Medicine"},{"key":"1060_CR22","unstructured":"Olson, J., Chen, P.-H. A., White, M., Brennan, N., & Gong, N. (2019). State drug policy effectiveness: Comparative policy analysis of drug overdose mortality. arXiv, 1909.01936. https:\/\/arxiv.org\/abs\/1909.01936"},{"issue":"5","key":"1060_CR23","doi-asserted-by":"publisher","first-page":"e0252090","DOI":"10.1371\/journal.pone.0252090","volume":"16","author":"K Papamihali","year":"2021","unstructured":"Papamihali, K., Collins, D., Karamouzian, M., Purssell, R., Graham, B., & Buxton, J. (2021). Crystal methamphetamine use in British Columbia, Canada: A cross-sectional study of people who access harm reduction services. PloS one, 16(5), e0252090.","journal-title":"PloS one"},{"key":"1060_CR24","doi-asserted-by":"publisher","unstructured":"Pearce, L. A., Min, J. E., Piske, M., Zhou, H., Homayra, F., Slaunwhite, A.,\u00a0\u2026\u00a0Nosyk, B. (2020). Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study. BMJ, 368, m772. https:\/\/doi.org\/10.1136\/bmj.m772","DOI":"10.1136\/bmj.m772"},{"key":"1060_CR25","doi-asserted-by":"publisher","unstructured":"Pijl, E. M., Alraja, A., Duff, E., Cooke, C., Dash, S., Nayak, N.,\u00a0\u2026\u00a0Fry, B. (2022). Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: An integrative review.\u00a0Substance Abuse Treatment, Prevention, and Policy, 17(1), 62. https:\/\/doi.org\/10.1186\/s13011-022-00463-5","DOI":"10.1186\/s13011-022-00463-5"},{"key":"1060_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103773","volume":"107","author":"A Pilarinos","year":"2022","unstructured":"Pilarinos, A., Kwa, Y., Joe, R., Thulien, M., Buxton, J. A., DeBeck, K., & Fast, D. (2022). Navigating opioid agonist therapy among young people who use illicit opioids in Vancouver, Canada. International Journal of Drug Policy, 107, Article 103773. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103773","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"1060_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13722-023-00402-0","volume":"18","author":"C Russell","year":"2023","unstructured":"Russell, C., Law, J., Imtiaz, S., Rehm, J., Le Foll, B., & Ali, F. (2023a). The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: A scoping review. Addict Sci Clin Pract, 18(1), 48.","journal-title":"Addict Sci Clin Pract"},{"key":"1060_CR28","doi-asserted-by":"publisher","unstructured":"Russell, C., Law, J., Bonn, M., Rehm, J., & Ali, F. (2023b). The increase in benzodiazepine-laced drugs and related risks in Canada: The urgent need for effective and sustainable solutions. International Journal of Drug Policy, 111(2023), Article 103933. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103933","DOI":"10.1016\/j.drugpo.2022.103933"},{"key":"1060_CR29","doi-asserted-by":"publisher","unstructured":"Russell, C., Ashley, J., Ali, F., Bozinoff, N., Corace, K., Marsh, D. C.,\u00a0\u2026\u00a0Lange, S. (2024). Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.\u00a0International Journal of Drug Policy, 127, 104343. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104343","DOI":"10.1016\/j.drugpo.2024.104343"},{"issue":"1","key":"1060_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10742-020-00228-2","volume":"21","author":"MS Schuler","year":"2021","unstructured":"Schuler, M. S., Griffin, B. A., Cerd\u00e1, M., McGinty, E. E., & Stuart, E. A. (2021). Methodological challenges and proposed solutions for evaluating opioid policy effectiveness. Health Services and Outcomes Research Methodology, 21(1), 21\u201341. https:\/\/doi.org\/10.1007\/s10742-020-00228-2","journal-title":"Health Services and Outcomes Research Methodology"},{"issue":"6","key":"1060_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/10826084.2024.2306221","volume":"59","author":"KA Simpson","year":"2024","unstructured":"Simpson, K. A., Bolshakova, M., Kirkpatrick, M. G., Davis, J. P., Cho, J., Barrington-Trimis, J., Kral, A. H., & Bluthenthal, R. N. (2024). Characterizing opioid withdrawal experiences and consequences among a community sample of people who use opioids. Substance Use & Misuse, 59(6), 886\u2013894.","journal-title":"Substance Use & Misuse"},{"key":"1060_CR32","doi-asserted-by":"publisher","unstructured":"Soc\u00edas, M. E., Dong, H., Wood, E., Brar, R., Richardson, L., Hayashi, K.,\u00a0\u2026\u00a0Milloy, M. J. (2020). Trajectories of retention in opioid agonist therapy in a Canadian setting.\u00a0International Journal of Drug Policy, 77, 102696. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102696","DOI":"10.1016\/j.drugpo.2020.102696"},{"key":"1060_CR33","unstructured":"Statistics Canada. (2023). Index of Remoteness, 2021. Statistics Canada."},{"key":"1060_CR34","doi-asserted-by":"publisher","unstructured":"Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F.,\u00a0\u2026\u00a0Walsh, S. L. (2020). Opioid use disorder. Nature Reviews Disease Primers, 6(1), 3. https:\/\/doi.org\/10.1038\/s41572-019-0137-5","DOI":"10.1038\/s41572-019-0137-5"},{"key":"1060_CR35","unstructured":"Taha, S., King, S., & Atif, S. (2022). Experiences of harm reduction service providers during dual public health emergencies in Canada: Substance use in Canada 2022. https:\/\/www.ccsa.ca\/sites\/default\/files\/2022-09\/CCSA-Experiences-of-Harm-Reduction-Service-Providers-en.pdf. Accessed 12 Jul 2024."},{"issue":"3","key":"1060_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/17456916211017860","volume":"17","author":"EA Waters","year":"2022","unstructured":"Waters, E. A., Kiviniemi, M. T., Hay, J. L., & Orom, H. (2022). Dismissing \u201cdon\u2019t know\u201d responses to perceived risk survey items threatens the validity of theoretical and empirical behavior-change research. Perspectives on Psychological Science, 17(3), 841\u2013851. https:\/\/doi.org\/10.1177\/17456916211017860","journal-title":"Perspectives on Psychological Science"},{"key":"1060_CR37","doi-asserted-by":"publisher","unstructured":"Yakovenko, I., Mukaneza, Y., Germ\u00e9, K., Belliveau, J., Fraleigh, R., Bach, P.,\u00a0\u2026\u00a0Team, C. R. I. i. S. M. g. d. (2024). Management of opioid use disorder: 2024 update to the national clinical practice guideline. CMAJ, 196(38), E1280-E1290. https:\/\/doi.org\/10.1503\/cmaj.241173","DOI":"10.1503\/cmaj.241173"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-025-01060-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-025-01060-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-025-01060-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:02:57Z","timestamp":1763503377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.17269\/s41997-025-01060-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.17269\/s41997-025-01060-2","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"value":"0008-4263","type":"print"},{"value":"1920-7476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was updated to delete affiliation 7 for author Farihah Ali.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Centre for Addiction and Mental Health (CAMH) Research Ethics Board (#2023\/169).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The funding source had no role in the design of this study, nor its execution, analyses, interpretation of data, or publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}